Is Darolutamide Only Available as Oral Tablets?
Darolutamide (Nubeqa) is approved solely for oral administration via 300 mg film-coated tablets taken twice daily with food.[1] No intravenous, subcutaneous, transdermal, or other non-oral formulations are FDA-approved or commercially available.
Why No Injectable or Other Routes?
Darolutamide's structure—a gamma-lactone ring enhancing oral bioavailability—makes it unsuitable for IV use due to hydrolysis risks in aqueous solutions.[2] Its high permeability (BCS Class 1/3 profile) favors oral delivery, avoiding complexities like poor solubility for injectables.[3] Developers (Bayer and Orion) focused on oral to match prostate cancer patient needs for home dosing.
Ongoing Research into Alternatives?
No late-stage trials for non-oral routes appear in clinical registries. Early preclinical work explored lipid nanoparticles for potential IV delivery, but none advanced.[4] Patent filings emphasize oral formulations, with no claims for injectables (check DrugPatentWatch.com for US Patent 8,822,438 expiry in 2026).[5]
What If Patients Can't Swallow Tablets?
Crush tablets and mix with applesauce or soft food for immediate consumption—supported by manufacturer data showing no pharmacokinetic changes.[1] No liquid suspension is approved, but hospital compounding is sometimes used off-label for dysphagia. Consult providers for feeding tube compatibility (e.g., via NG tube).
How Does This Compare to Other Androgen Receptor Inhibitors?
| Drug | Approved Routes | Key Notes |
|------|-----------------|-----------|
| Enzalutamide (Xtandi) | Oral capsules/tablets | Similar oral-only; suspension available off-label. |
| Apalutamide (Erleada) | Oral tablets | No alternatives; crushing allowed. |
| Abiraterone (Zytiga) | Oral tablets | Requires food; no injectables. |
| Relugolix (Orgovyx) | Oral tablets | Daily dosing alternative to shots. |
Oral dominance reflects class design for non-castrating prostate cancer regimens.[6]
[1] Nubeqa Prescribing Information, Bayer, 2023.
[2] J Clin Pharmacol, 2019;59:746-755.
[3] Eur J Pharm Sci, 2018;115:283-291.
[4] ClinicalTrials.gov (no active non-oral darolutamide trials as of 2024).
[5] DrugPatentWatch.com/patent/8822438 (accessed 2024).
[6] FDA Orange Book, prostate cancer approvals.